ACROSTUDY: the Italian experience

Endocrine

Volumn 48, Issue 1, 2015, Pages 334-341

  Grottoli, S ^a   Maffei, P ^b   Bogazzi, F ^c   Cannavo S ^d   Colao, A ^e   Ghigo, E ^a   Gomez, R ^f   Graziano, E ^f   Monterubbianesi, M ^f   Jonsson, P ^f   De Marinis, L ^g  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f PFIZER INC   (United States)

^g FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Acromegaly; Efficacy; Italy; Pegvisomant; Safety

Indexed keywords

CABERGOLINE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; HORMONE ANTAGONIST; HUMAN GROWTH HORMONE;

ACROMEGALY; ACROSTUDY; ACUTE HEPATITIS; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DIPLOPIA; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE SURGERY; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REGISTER; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY; ADOLESCENT; ANALOGS AND DERIVATIVES; CHILD; DOSE RESPONSE; ENZYMOLOGY; LIVER; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; YOUNG ADULT;

ACROMEGALY; ADOLESCENT; ADULT; AGED; CHILD; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; ITALY; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942593816     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0393-9     Document Type: Article

References (24)

1. A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, A consensus on criteria of cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010)
2. A. Giustina, P. Chanson, D. Kleinberg, M. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K. Ho, F.F. Casanueva, S. Melmed, Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinology 10, 243–248 (2014)
3. S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509–1517 (2009)
4. M.O. Thorner, C.J. Strasburger, Z. Wu, M. Straume, M. Bidlingmaier, S.S. Pezzoli, K. Zib, J.C. Scarlett, W.F. Bennett, Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J. Clin. Endocrinol. Metab. 84, 2098–2103 (1999)
5. J.J. Kopchick, C. Parkinson, E.C. Stevens, P.J. Trainer, Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev. 23, 623–646 (2002)
6. A. Colao, G. Arnaldi, P. Beck-Peccoz, R. Cozzi, E. degli Uberti, L. De Marinis, E. De Manis, D. Ferone, V. Gasco, A. Giustina, S. Grottoli, G. Lombardi, P. Maffei, E. Martino, F. Minuto, R. Pivonello, E. Ghigo, Pegvisomant in acromegaly: why, when, how. J. Endocrinol. Invest. 30, 693–699 (2007)
7. M. Gola, S. Bonadonna, G. Mazziotti, G. Amato, A. Giustina, Resistance to somatostatin analogs in acromegaly: an evolving concept ? J. Endocrinol. Invest. 29, 86–93 (2006)
8. A. Giustina, M.D. Bronstein, F.F. Casanueva, P. Chanson, E. Ghigo, K.K. Ho, A. Klibanski, S. Lamberts, P. Trainer, S. Melmed, Current management practices for acromegaly: an international survey. Pituitary 14, 125–133 (2011)
9. P.J. Trainer, W.M. Drake, L. Katznelson, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342, 1171–1177 (2000)
10. A.J. van der Lely, R.K. Hutson, P.J. Trainer, Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358, 1754–1759 (2001)
11. C.J. Strasburger, M. Buchfelder, M. Droste, K. Mann, G.K. Stalla, B. Saller, German Pegvisomant Investigators: experience from the German Pegvisomant Observational Study. Horm. Res. 68, 70–73 (2007)
12. M. Buchfelder, D. Weigel, M. Droste, K. Mann, B. Saller, K. Brübach, G.K. Stalla, M. Bidlingmaier, C.J. Strasburger, On behalf of the investigators of the German Pegvisomant Observational Study, Pituitary tumour size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur. J. Endocrinol. 161, 27–35 (2009)
13. A.J. van der Lely, B.M. Biller, T. Brue, M. Buchfelder, E. Ghigo, R. Gomez, J. Hey-Hadavi, F. Lundgren, N. Rajicic, C.J. Strasburger, S.M. Webb, M. Koltowska-Häggström, Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 97, 1589–1597 (2012)
14. I. Schreiber, M. Buchfelder, M. Droste, K. Forssmann, K. Mann, B. Saller, C.J. Strasburger, German Pegvisomant Investigators. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156, 75–82 (2007)
15. M. Buchfelder, S. Schlaffer, M. Droste, K. Mann, B. Saller, K. Brübach, G.K. Stalla, C.J. Strasburger, German Pegvisomant Observational Study. The German ACROSTUDY: past and present. Eur. J. Endocrinol. 161, S3–S10 (2009)
16. P.J. Trainer, ACROSTUDY: the first 5 years. Eur. J. Endocrinol. 161, S19–S24 (2009)
17. I. Bernabeu, M. Marazuela, T. Lucas, L. Loidi, C. Alvarez-Escolá, M. Luque-Ramírez, E. Fernandez-Rodriguez, A.E. Paniagua, C. Quinteiro, F.F. Casanueva, Pegvisomantinduced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s syndrome. J. Clin. Endocrinol. Metab. 95, 2147–2154 (2010)
18. J.H. Buhk, S. Jung, M.N. Psychogios et al., Tumour volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J. Clin. Endocrinol. Metab. 95, 552–558 (2010)
19. T. Brue, F. Castinetti, F. Lundgren, S. Göricke, S. Hartz, S. Schulz-Heise, R. Klingebiel, M. Forsting, H. Brückmann, A. Dörfler, M. Jordan, M. Buchfelder, M. Knauth, Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur. J. Endocrinol. 161, S11–S17 (2009)
20. M. Arosio, G. Reimondo, E. Malchiodi, P. Berchialla, A. Borraccino, L. De Marinis, R. Pivonello, S. Grottoli, M. Losa, S. Cannavò, F. Minuto, M. Montini, M. Bondanelli, E. De Menis, C. Martini, G. Angeletti, A. Velardo, A. Peri, M. Faustini-Fustini, P. Tita, F. Pigliaru, G. Borretta, C. Scaroni, N. Bazzoni, A. Bianchi, M. Appetecchia, F. Cavagnini, G. Lombardi, E. Ghigo, P. Beck-Peccoz, A. Colao, M. Terzolo, Italian Study Group of Acromegaly, Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur. J. Endocrinol. 167, 189–198 (2012)
21. A. Bianchi, F. Valentini, R. Iuorio, M. Poggi, R. Baldelli, M. Passeri, A. Giampietro, L. Tartaglione, S. Chiloiro, M. Appetecchia, P. Gargiulo, A. Fabbri, V. Toscano, A. Pontecorvi, L. De Marinis, Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 21(32), 40 (2013)
22. C. Parkinson, P. Burman, M. Messig, P.J. Trainer, Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J. Clin. Endocrinol. Metab. 92, 190–195 (2007)
23. R. Cozzi, M. Montini, R. Attanasio, M. Albizzi, G. Lasio, S. Lodrini, P. Doneda, L. Cortesi, G. Pagani, Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J. Clin. Endocrinol. Metab. 91, 1397–1403 (2006)
24. H. Biering, B. Saller, J. Bauditz, M. Pirlich, B. Rudolph, A. Johne, M. Buchfelder, K. Mann, M. Droste, I. Schreiber, H. Lochs, C.J. Strasburger, Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur. J. Endocrinol. 154, 213–220 (2006)